,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2011-12-05 23:45:00,We maintain our Neutral rating on Boston Scientific Corporation ( BSX ) as the shares appear to be fairly valued.,0.10000591725111008,0.06684216111898422,0.8331518769264221,neutral,0.033163756132125854
1,2011-12-05 23:45:00,"Headquartered in Natick, Massachusetts, Boston Scientific is a leading player in the field of medical devices.",0.5856661200523376,0.009816773235797882,0.4045170545578003,positive,0.5758493542671204
2,2011-12-05 23:45:00,"Despite several initiatives undertaken by the company to revive its flagging top line, we toe a more cautious line as the core segments, ICDs and DES (contributing 40%), as per sales, continued to witness several headwinds.",0.11665557324886322,0.8394491672515869,0.04389524832367897,negative,-0.7227935791015625
3,2011-12-05 23:45:00,"The Cardiac Rhythm Management ( CRM ) market in the US has been impacted by physician reaction to a study result published by the Journal of the American Medical Association regarding evidence-based guidelines for ICD implants, US Department of Justice's investigation into hospitals' ICD implants and the ongoing physician alignment to hospitals and competitive pricing pressures.",0.025398634374141693,0.9217090010643005,0.052892379462718964,negative,-0.8963103890419006
4,2011-12-05 23:45:00,"The DES business in the US continues to suffer pricing pressure, lower procedural volume and penetration rates.",0.021688982844352722,0.9134312272071838,0.06487985700368881,negative,-0.8917422294616699
5,2011-12-05 23:45:00,"As a confidence booster, recent product launches should come to the company's aid.",0.9024516940116882,0.015106606297194958,0.08244170248508453,positive,0.8873450756072998
6,2011-12-05 23:45:00,"We are encouraged by the US approval of Promus Element Plus stent, which comes well ahead of the original expectation of a mid-2012 approval.",0.8826203942298889,0.013849212788045406,0.10353035479784012,positive,0.8687711954116821
7,2011-12-05 23:45:00,Promus Element represents $200 million in additional annualized gross margin contribution from the US and Japan at the end of 2012.,0.5319488048553467,0.01336944755166769,0.45468172430992126,positive,0.518579363822937
8,2011-12-05 23:45:00,This is a part of the targeted $650-$750 million opportunity for improvement in operating profit over the next few years.,0.9433546662330627,0.016330841928720474,0.04031452536582947,positive,0.9270238280296326
9,2011-12-05 23:45:00,The success of Ion and Promus Element Plus in the US coupled with Johnson & Johnson 's ( JNJ ) announcement of exiting the DES business by the end of 2011 and the expected launch of Promus Element in Japan should enable the company to improve its DES market share.,0.9560229182243347,0.017479155212640762,0.02649790421128273,positive,0.9385437369346619
10,2011-12-05 23:45:00,"Moreover, we believe the recent US approval of Energen and Punctua CRT-Ds and ICDs should support the company's 2012 growth story.",0.9193958044052124,0.012988429516553879,0.06761579215526581,positive,0.906407356262207
11,2011-12-05 23:45:00,"Meanwhile, Boston Scientific has resorted to the restructuring route to strengthen its operational effectiveness and efficiency, increase competitiveness and support new investments.",0.9286205172538757,0.015187805518507957,0.056191641837358475,positive,0.9134327173233032
12,2011-12-05 23:45:00,The program is expected to reduce annual pre-tax operating expenses by $225-$275 million exiting 2013 and a part of this saving will be invested back in the business to drive growth going ahead.,0.8411182165145874,0.05688468739390373,0.10199715942144394,positive,0.7842335104942322
13,2011-12-05 23:45:00,"Although benefits from these programs will not be accrued in 2011, these steps should strengthen the company in the long term.",0.9226070642471313,0.01516256108880043,0.06223041191697121,positive,0.9074444770812988
14,2011-12-05 23:45:00,"Moreover, having established a strong foothold in the US and Europe, Boston Scientific is looking to consolidate its presence in the emerging markets of Brazil, India and China.",0.9482540488243103,0.014476793818175793,0.037269145250320435,positive,0.9337772727012634
15,2011-12-05 23:45:00,Sales in these regions advance at a double-digit clip during the reported quarter.,0.8746262788772583,0.017359741032123566,0.10801398009061813,positive,0.8572665452957153
16,2011-12-05 23:45:00,"With the recent launch of Promus Element in China and some anticipated pricing approvals in India, contribution from these regions is expected to rise further in 2012.",0.9212000370025635,0.013581889681518078,0.06521809846162796,positive,0.9076181650161743
17,2011-12-05 23:45:00,"Based on investments made in sales representatives, dealers and infrastructure, the company is well placed to increase its single-digit market share in China and India.",0.9532474279403687,0.016327835619449615,0.030424783006310463,positive,0.9369195699691772
18,2011-12-05 23:45:00,The combined DES market in China and India is currently estimated at $700 million growing at a 20% rate.,0.635932981967926,0.011065405793488026,0.35300159454345703,positive,0.6248675584793091
19,2011-12-05 23:45:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
